US 11,832,616 B2
Anti-viral paints and coatings and articles comprising same
Claude Steven McDaniel, Austin, TX (US)
Assigned to REACTIVE SURFACES LTD., LLP, Austin, TX (US)
Filed by REACTIVE SURFACES LTD., LLP, Austin, TX (US)
Filed on Jul. 16, 2021, as Appl. No. 17/378,537.
Application 17/378,537 is a division of application No. 17/037,415, filed on Sep. 29, 2020, granted, now 11,102,983.
Application 17/037,415 is a continuation in part of application No. 16/266,096, filed on Feb. 3, 2019.
Claims priority of provisional application 63/036,480, filed on Jun. 9, 2020.
Prior Publication US 2021/0352915 A1, Nov. 18, 2021
Int. Cl. A01N 63/40 (2020.01); A01N 63/50 (2020.01); A01N 25/10 (2006.01)
CPC A01N 63/40 (2020.01) [A01N 25/10 (2013.01); A01N 63/50 (2020.01)] 26 Claims
 
1. A product effective in mitigating contamination of a surface thereof by particles of a coronavirus for which an enveloped bacterial virus characterized by having a lipid-rich viral membrane envelope is a biological surrogate, wherein the product is made by a process comprising the steps of:
applying an anti-viral functionalized coating composition on a surface of a substrate to create an anti-viral functionalized surface thereof, wherein the anti-viral functionalized coating composition comprises an effective amount of an anti-viral additive admixed with a specified amount of a polymeric coating composition, wherein the anti-viral additive comprises antimicrobial peptide and lipolytic enzyme, wherein said antimicrobial peptide comprises SEQ ID NO. 40, wherein the effective amount of the anti-viral additive and the specified amount of the polymeric coating composition jointly cause the anti-viral functionalized surface to provide an additive-induced amount of infective particles of a biological surrogate when the biological surrogate is brought into contact with the anti-viral functionalized surface that is at least 70% less than a baseline amount of infective particles of the biological surrogate, wherein a surface of a layer of the polymeric coating composition supports presence of the baseline amount of infective particles of the biological surrogate when the biological surrogate is brought into contact with the surface of the layer of the polymeric coating composition and wherein the infective particles comprise an enveloped bacterial virus having a lipid-rich viral membrane envelope.